Details of the Drug
General Information of Drug (ID: DMKZQ3I)
Drug Name |
4-iodo-1H-indazole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4-iodo-1H-indazole; 885522-11-2; 4-Iodoindazole; 4-IODO (1H)INDAZOLE; CHEMBL246534; zlchem 1146; PubChem21944; SCHEMBL358061; 4-Iodo-1H-indazole, 95%; 4-IODO-(1H)-iNDAZOLE; 1H-INDAZOLE, 4-IODO-; CTK8B7170; ZLD0614; DTXSID10646276; MolPort-009-197-588; CJQXSPSUIGJNJX-UHFFFAOYSA-N; ZX-RL006042; BCP26449; ZINC14983484; BDBM50209235; ANW-56585; CI-483; AKOS015853740; FCH1325887; VI20042; QC-2871; PB27826; RP05951; AS-50534; AJ-65949; EN002531; KB-39256; OR308061; AK-27887; TC-062829; DB-023141; AB0037276; ST1100625; AX8158792; Y4536; AM20041322
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 244.03 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||